Ultragenyx Pharmaceutical Obtains $75,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dd613505-2bad-4d65-9c9e-be01add9222c&Preview=1 - Date
12/20/2012 - Company Name
Ultragenyx Pharmaceutical - Mailing Address
77 Digital Drive Novato, CA 94949 - Company Description
Ultragenyx is a new startup focused on developing therapeutics for rare diseases. The company is lead by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical, and will build on management’s experience in choosing and developing products with clear mechanisms of action in untreated rare diseases. - Website
http://www.ultragenyx.com - Transaction Type
Venture Equity - Transaction Amount
$75,000,000 - Transaction Round
Series B - Proceeds Purposes
The company will use the proceeds to advance development of its meaning clinical stage programs, UX001 and UX003, as well as other undisclosed programs. - M&A Terms
- Venture Investor
Adage Capital Management - Venture Investor
TPG Biotech - Venture Investor
T. Rowe Price - Venture Investor
BlackRock - Venture Investor
Sanofi - Venture Investor
Shire Pharmaceuticals - Venture Investor
Fidelity BioSciences - Venture Investor
Healthcap Venture Capital - Venture Investor
Pappas Ventures
